News
European Commission approves Pfizer’s HYMPAVZI for adults and adolescents with severe hemophilia A or...
The European Commission (EC) has granted marketing authorization for Pfizer's HYMPAVZI (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of...
Glox Therapeutics awarded £1m PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant...
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has secured £1 million in grant funding from...
UCB receives U.S. FDA approval for BIMZELX as first IL-17A and IL-17F inhibitor for...
The U.S. Food and Drug Administration (FDA) has approved UCB's BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS)....
